Mauna Kea announced successful reimbursement coverage for the use of confocal laser endomicroscopy ("CLE") for Barrett's Esophagus ("BE") in France. This further validates the clinical utility of Cellvizio and is testimony to Mauna Kea's ability to deliver on its strategic milestones for 2019, as set out in our recent report. With reimbursement in place in France, Mauna Kea is delivering on its promise to drive revenue generation outside the US by providing clinicians with a strong incentive for ....
19 Jun 2019
Reimbursement decision facilitates Cellvizio penetration in France
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Reimbursement decision facilitates Cellvizio penetration in France
Mauna Kea Technologies SA Class O (0P5I:LON) | 0 0 0.2% | Mkt Cap: 75.0m
- Published:
19 Jun 2019 -
Author:
Martin Piehlmeier -
Pages:
5
Mauna Kea announced successful reimbursement coverage for the use of confocal laser endomicroscopy ("CLE") for Barrett's Esophagus ("BE") in France. This further validates the clinical utility of Cellvizio and is testimony to Mauna Kea's ability to deliver on its strategic milestones for 2019, as set out in our recent report. With reimbursement in place in France, Mauna Kea is delivering on its promise to drive revenue generation outside the US by providing clinicians with a strong incentive for ....